A series of 27 B-cell lymphomas (designated the CH series), induced in B1O.H-2aH4bp/Wts mice by intense adoptive immunization with sheep erythrocytes, was found to represent a subset of the total B-cell repertoire. This subset was characterized by expression of a limited number of Ig heavy chain variable regions, as evidenced by the presence of crossreactive idiotypes and common antigen binding specificities. Twenty-one of the 27 CH lymphomas studied were classified into five groups, defmed by a particular cross-reactive idiotype; four of these groups were linked in a single network. Seven of 16 idiotypes defined by absorption analysis were present on lymphomas bearing either K or A light chains and so were localized to the heavy chain variable region. The surface Ig on 14 CH lymphomas was found to be specific for epitopes on certain erythrocytes (bromelain-treated autologous erythrocytes, sheep, and chicken erythrocytes) or E. coUl. We propose that the CH lymphomas represent the malignant counterparts of a subset of idiotypically related, normal B cells in B1O.H2aH4bp/Wts mice. Perturbation of this idiotype network, by hyperimmunization with an antigen for which some of the members are specific (sheep erythrocytes), increases the risk for neoplasia. Possible mechanisms for this are discussed.
2aH4bp/Wts mice. Perturbation of this idiotype network, by hyperimmunization with an antigen for which some of the members are specific (sheep erythrocytes), increases the risk for neoplasia. Possible mechanisms for this are discussed.
Mice of the double congeneic strain, B1O.H-2aHW4bp/Wts (2a4b), display a high incidence of lymphoma following intense adoptive immunization with sheep erythrocytes (SRBC). The tumors that arise comprise a heterogeneous group, including the UNC series of T-cell lymphomas (1) , the CH series of B-cell lymphomas (2) , and a set of lymphomas which are not readily characterized as belonging to either the B-cell or T-cell lineage (unpublished data). Presently available data are insufficient to define the etiology ofthis disease, but we had found previously that xenogeneic anti-idiotype (anti-Id) sera raised against the surface IgM of CH1 and of CH2 each reacted with 1 other of the first 11 B-cell lymphomas described (CH9 and CH5, respectively) (3). This suggested that a limited subset of the total normal Id repertoire might be expressed by the CH lymphomas [Ids are sets of antigenic determinants (called idiotopes) associated with Ig variable (V) regions] (4). We also had found that the surface Ig of CH12 was specifically reactive with an epitope present on SRBC, suggesting that adoptive immunization had led to the expansion of a subset of B cells with neoplastic potential (5) .
In pursuit of this possible link between antigen-driven B cell proliferation and lymphomagenesis, we now report the results of a study of the surface Ig borne by 27 different B-cell lymphomas of 2a4b mice. The data demonstrate extensive sharing of idiotopes, several of which can be localized to the heavy chain variable (VH) region; 21 of the tumors can be arranged in five cross-reactive groups, four of which are linked in a single network. Furthermore, 14 of these lymphomas bear surface Ig specific for epitopes present on certain erythrocytes [SRBC, chicken erythrocytes (ChRBC), and autologous erythrocytes treated with the proteolytic enzyme, bromelain] or Escherichia coli. We interpet this to imply that defective regulation of a subset of Id-related B cells contributes to the susceptibility of 2a4b mice to antigendriven lymphomagenesis.
MATERIALS AND METHODS Animals. 2a4b mice were bred and maintained in our pathogen-free mouse colony. This strain was derived from selected F2 progeny of B10.A x B10.129(21M) mice as described (6) . BALB/c mice were purchased from Charles River Breeding Laboratories.
New Zealand White rabbits were used for antiserum production.
Tumors. The CH series of B-cell lymphomas was induced in 2a4b mice by adoptive hyperimmunization with SRBC. The one exception to this was CH19; it arose in a 487-day-old unmanipulated 2a4b mouse. Details concerning the inductions of CHI-CH12 have been reported (2) . The induction protocols for CH15-CH39 will be presented elsewhere. These tumors have been maintained by serial transplantation of ascites or splenic tumor cells in syngeneic animals. MOPC104E (provided by J. Folds) and TEPC183 (Litton Bionetics; National Cancer Institute Contract N01-CB-94326) plasmacytomas (7) were maintained by transplantation in pristane-primed BALB/c mice.
Characterization of Cell Surface Antigens. All of the CH lymphomas bear surface IgM (see Table 1 
,u Kt tThese antisera were extensively absorbed so that each reacted with >95% of the tumor cells (against which it was raised) and with no detectable normal spleen cells. Either MOPC104E (for anti-CH1.1, anti-CH1.2, and anti-CH2) or TEPC183 (for anti-CH6, anti-CH7, anti-CH9, anti-CH10, and anti-CH27) immobilized myeloma proteins and normal spleen cells were used in the absorptions. Anti-CH1 (1.1 and 1.2) and anti-CH2 were absorbed further with CH2 and CH1 cells, respectively.
Anti-CH5 and apti-CH12 were absorbed with CH15 cells and normal spleen cells. *Secreted immunoglobulin light and heavy chains. lished data). All of the CH lymphomas except CH12 and CH27 express Fc-fragment receptors, but only CH25 expresses detectable receptors for the third complement component (CH31 and CH34 hive yet to be tested for both receptors).
The reagents used to measure the level of the Ly-1 antigen were: rat monoclonal anti-Ly-1 antibody (53-73.1) (8), followed by biotin-labeled monoclonal mouse (SJL) anti-rat K light chain antibody (MAR18.5) (9) and then avidinphycoerythrin conjugate (Becton Dickinson Monoclonal Center). For negative controls, the first antibody was either omitted or substituted with the rat monoclonal anti-Thy-1.2 antibody (30-H12) (8) . An EPICS V flow cytometer (Coulter) equipped with a logarithmic amplifier was used to measure the fluorescence intensity of each sample.
Rosette Assays. The erythrocytes and E. coli rosette assays have been described (5, 10) . In order to determine if the binding of antigen was due to the surface Ig, the tumor cells were incubated with anti-Ig antisera in RPMI 1640 medium for 60 min at 37°C (capping conditions) before the addition of erythrocytes or E. coli. The remainder of the assay was performed as described.
Preparation of Anti-Id Antisera. Rabbit antisera were raised against the detergent-solubilized affinity-purified surface Ig of the CH lymphomas as described (11) . Each serum (including normal rabbit serum) was absorbed extensively by using the procedures described below. An anti-Id antiserum was considered specific when it reacted with >95% of the immunizing tumor cells but not with a detectable number of normal 2a4b splenocytes (in an indirect immunofluorescence assay) (11) .
Anti-Id sera raised against the IgM X light chain-bearing tumors (CH1 and CH2) were absorbed with immobilized MOPC104E (,,X) myeloma protein, while those sera raised against most of the IgM K light chain-bearing tumors (CH6, CH7, CH9, CH10, and CH27) were absorbed with immobilized TEPC183 (A,K) myeloma protein. Anti-CHi and anti-CH2 Id sera were absorbed further with CH2 and CH1 cells, respectively. Since both CH5 and CH12 were shown to express idiotopes shared by TEPC183, anti-Id sera raised against these tumors were absorbed with another, nonidiotypically related, IgM K chain-bearing lymphoma, CH15. A final absorption with 2a4b splenocytes was performed for all antisera.
Each antiserum is referred to as an anti-CHXId, where X corresponds to the number of the CH lymphoma against which the antiserum was raised. In one case (CH1), antisera produced in two rabbits displayed different reactivity patterns (Table 1) amounts of Ly-1 (+: CH19, CH21, CH23, and CH29; +/-:
CH15, CH27, CH28, CH32, CH34, CH35, and CH36; "trace": CH31 and CH38) (see Fig. 1 for histograms of representative lymphomas). A subset of normal B cells (12) and several other B-cell lymphomas (13) also have been shown to express Ly-1. Specificity of Anti-Id Sera. We raised xenogeneic anti-Id sera against the surface Ig borne by nine CH lymphomas and, after exhaustive absorptions, tested each for its specificity in an indirect immunofluorescence assay. The results of these tests for two representative anti-Ids (anti-CH12 and anti-CH27) are shown in Fig. 2 Further proof of the specificity of these sera came from antigen binding inhibition studies (see Table 4 ), which show that only specific anti-Ids can inhibit the rosette formation of erythrocytes or E. coli with the appropriate tumors. Anti-CH10 Id, for example, abrogated the ability of CH10 to bind E. coli, whereas anti-CH9 and anti-CH27 Id did not.
Analysis of Cross-Reactive Ids (IdX). We tested the 10 anti-Id sera against all of the CH lymphomas (Table 1 ). This analysis revealed that 21 of the 27 CH lymphomas bore IdX, as defined by 7 ofthe anti-Ids. We classified these tumors into five groups, realizing that four of them overlapped. The five groups and the anti-Ids that define them are (t) CH1 IdX (CR1, CH9, CH15, CH26, CH34, and CH39; anti-CH1.1 and anti-CH9 Ids), (ii) CH2 IdX (CH2, CH5, CH27, and TEPC183; anti-CH2 and anti-CH5 Ids), (iii) CH10 IdX (CH10, CH29, CH31, CH33, and CH36; anti-CH1O Id), (iv) CH12 IdX (CH12, CH23, CH25, CH32, CH38, CH39, and TEPC183; anti-CH12 Id), and (v) CH27 IdX (CH25, CH27, CH28, CH32, and CH35; anti-CH27 Id). The CH1, CH2, CH12, and CH27 IdX groups (which include 16 lymphomas) are linked together by the following tumors: CH25, CH27, CH32, CH39, and TEPC183 (i.e., these tumors are present in more than one IdX group).
In order to determine the minimum number of idiotopes expressed by the lymphomas in each IdX group, we exhaustively absorbed each anti-Id with each of the tumors with which it reacted. Each anti-Id was then retested on all of the other tumors in the IdX group. If a tumor then failed to react with an absorbed anti-Id, it indicated that the tumor tested and the one used in the absorption shared at least one idiotope. Ifthe immunizing tumor still tested positive, at least two idiotopes were assigned to it: one shared and one not shared with the lymphoma used in the absorption. The results of these analyses are summarized in Table 2 .
A minimum of 16 idiotopes is expressed by 23 of the 27 CH lymphomas. Only 4 idiotopes (b, n, o, and p) appear to be private (i.e., expressed by only 1 tumor); the rest are shared. At least 7 (a, d, e, f, i, j, and k) of the 12 shared idiotopes are located on the VH region, as evidenced by their expression on lymphomas bearing either K or X light chains (presently available data are uninformative regarding the involvement of VH or light chain V regions in the expression of the other 9 idiotopes). Interestingly, each of the tumors that link four of the five IdX groups bears at least 1 of these idiotopes. Four of these idiotopes (e, f, i, and k) are also expressed by the BALB/c myeloma protein, TEPC183.
Antigen Specifcities of CH Lymphomas. Fourteen of the 27 CH lymphomas bind determinants on the surfaces of certain erythrocytes or E. coli or both (Table 3 ). We first discovered that CH12 formed rosettes with SRBC and ChRBC (5). Subsequently we found that CH12, as well as CH9, CH15, 
, not done. *These idiotopes were defined by 10 xenogeneic anti-Id sera. If an anti-Id serum reacted with more than one tumor, then it was absorbed with each tumor and retested on all ofthe lymphomas with which it had reacted. Tumors that did not now react with the absorbed serum were assigned one idiotope (shared by the lymphoma used in the absorption). Two idiotopes were assigned to immunizing tumors which still tested positive with the absorbed anti-Id serum (one was unique to the immunizing tumor, with respect to the one used in the absorption, and the other was shared by the two tumors).
CH23, CH27, CH28, CH32, CH34, and CH35, formed rosettes with syngeneic erythrocytes that had been treated with bromelain (BrMRBC) (the tumors did not bind untreated mouse erythrocytes). CH27, CH28, CH32, CH34, and CH35 also formed rosettes with ChRBC and SRBC, although the percentage of CH34 cells that bound these erythrocytes was low (15% and 14%, respectively).
CH34 formed rosettes not only with erythrocytes but also with fluoresceinated E. coli (since CH34 did not bind the fluoresceinated second step used in the indirect immunofluorescence assay, we ruled out fluorescein as the specific hapten). CH23 also bound E. coli as well as BrMRBC, but to a lesser extent (13% rosette-forming cells in both tests). CH1, CH10, CH25, CH31, and CH38 all displayed high percentages (>50%) of rosette-forming cells with E. coli.
For every tumor tested, the binding of erythrocytes or E. coli was attributable to the surface 1g. Pretreatment of CH10, CH12, CH27, CH32, CH34, and CH35 with anti-Ig reagents under capping conditions drastically reduced the numbers of rosette-forming cells (Table 4) . Furthermore, supernatants from the CH9, CH12, CH15, CH27, and CH28 hybridomas agglutinated the appropriate erythrocytes (unpublished data).
DISCUSSION
The CH lymphomas display a restricted repertoire of idiotopes and antigen binding specificities. Fourteen of the 27 lymphomas we examined bore surface Ig specific for epitopes on certain erythrocytes or E. coli or both (Table 3) . Twentyone CH lymphomas bore at least 1 of 12 shared idiotopes as defined by seven xenogeneic anti-Id sera (Table 2) . Of these 12 idiotopes, at least 7 were located in the VH domain, as evidenced by their presence on lymphomas bearing either K CH1  CH2  CH4  CH5  CH6  CH7  CH9  CH10  CH12  CH15  CH19  CH21  CH23  CH25  CH26  CH27  CH28  CH29  CH30  CH31  CH32  CH33  CH34  CH35  CH36  CH38  CH39   ++   ND or A light chains (the data were uninformative regarding the locations of the other idiotopes). Based on these observations, we hypothesize that the CH lymphomas derive from a subset of B cells, defined by the expression of a limited number of VH gene products.
Additional evidence suggests that the CH lymphomas represent a subset of B cells. Included among the nine CH lymphomas that bear surface Ig specific for a determinant(s) on BrMRBC, is a subset of tumors that also bind SRBC and ChRBC (the ChRBC determinants are not Forssman, major histocompatibility complex, or major blood group antigens; unpublished data). To our knowledge, no murine Ig with this specificity has been reported previously. Therefore, these tumors do not represent a population of B cells with typical anti-SRBC or anti-ChRBC specificies.
It is interesting to note that among the nine BrMRBC-binding lymphomas, all but one (CH9) bear detectable amounts of Ly-1. Ly-1 is a differentiation antigen present on all T cells (14) and on 1-2% and 5-10% of splenic B cells in normal and young NZB mice, respectively (12) . Furthermore, Hayakawa et al. (15) have shown that all of the B cells that secreted anti-BrMRBC antibodies (in both NZB and normal mice) were Ly-l+. They proposed that Ly-1+ B cells are responsible for most of the IgM autoantibodies found in autoimmune and normal mice. Since at least two-thirds of the CH lymphomas are Ly-1, they may be derived from this subpopulation. Indeed, there does appear to be a correlation between the expression of Ly-1 and at least two CH-associated IdX (CH12 and CH27 IdX) on normal 2a4b B cells. All 2a4b B cells that can be induced to secrete anti-BrMRBC Proc. NaiL Acad ScL USA 82 (1985) 3803 antibodies by treatment with lipopolysaccharide bear Ly-1. Pretreatment of these cells with anti-CH12 and anti-CH27 Id sera plus complement reduces the number of BrMRBCspecific plaques by approximately half (16).
At least two mechanisms may be involved in the etiology of CH lymphomas: one involves antigen recognition, and the other, Id recognition. It is reasonable to assume that antigendriven selection is involved in the etiology of the 6 SRBCbinding lymphomas, since SRBC comprised at least a part of the immunizing antigen used to induce each of them. However, antigen drive cannot be the sole factor contributing to B-cell lymphomagenesis in 2a4b mice, as the remaining 21 tumors do not bind SRBC, even though all but 1 (CH19) arose following intense adoptive immunization from SRBC. To account for these tumors, we propose that a second mechanism involving the recognition (or lack thereof) of a IdX, may also be involved in the development of these B-cell lymphomas. The normal B-cell counterparts in the CH lymphomas may all express a common VH-encoded "regulatory" idiotope, as described by Bona et al. (17) and, as such, may all be members of a miniregulatory network. Perturbation of this putative network by hyperimmunization with SRBC, an antigen for which some of the members are specific, in some way increases the risk of the members for neoplasia. The peculiar propensity for 2a4b mice to develop B-cell lymphomas under these conditions, might reflect the absence of an effective idiotype suppressor system, specific for the IdX of this network. These findings may have relevance to the use of anti-Id antibodies for diagnosis or treatment of B-cell lymphomas. Since the CH lymphomas, and possibly others, represent an idiotypically restricted subset of B cells, it should be possible to treat the majority of these tumors with a mixture of a few anti-Id reagents. The presence of several CH-associated idiotopes on the TEPC183 Ig (a BALB/c myeloma protein) suggests that the putative Id-related mechanism involved in the etiology of this series may not be unique to 2a4b mice. If this is so, then oligospecific anti-Id therapy may be possible for a number of B-cell malignancies.
